Regulation of YAP through an Akt-dependent process by 3, 3′-diindolylmethane in human colon cancer cells

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1992-1998

  Li, Xiu Juan ^a   Leem, Sun Hee ^b   Park, Man Hee ^c   Kim, Soo Mi ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Dong A University   (South Korea)

^c Catholic University of Pusan   (South Korea)

Author keywords

3,3 diindolylmethane; Apoptosis; Human colon cancer cells; LY294002; PI3K Akt pathway; YAP

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3,3' DIINDOLYLMETHANE; CELL PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; YAP PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL KILLING; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME INACTIVATION; HIPPO SIGNALING; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULAR INTERACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; COLONIC NEOPLASMS; DRUG COMBINATIONS; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; INDOLES; MORPHOLINES; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84891905701     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2121     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Leystra AA, Deming DA, Zahm CD, et al: Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res 72: 2931-2936, 2012.
4. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
5. Pal I and Mandal M: PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 33: 1441-1458, 2012.
6. Oldham S and Hafen E: Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol 13: 79-85, 2003.
7. Hietakangas V and Cohen SM: Regulation of tissue growth through nutrient sensing. Annu Rev Genet 43: 389-410, 2009.
8. Michlig S, Harris M, Loffing J, Rossier BC and Firsov D: Progesterone down-regulates the open probability of the amiloride-sensitive epithelial sodium channel via a Nedd4-2- dependent mechanism. J Biol Chem 280: 38264-38270, 2005.
9. Saif MW and Chu E: Biology of colorectal cancer. Cancer J 16: 196-201, 2010.
10. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499, 2009.
11. Tenbaum SP, Ordonez-Moran P, Puig I, et al: beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18: 892-901, 2012.
12. Abdul-Ghani R, Serra V, Gyorffy B, et al: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743-1752, 2006.
13. Martini M, Ciraolo E, Gulluni F and Hirsch E: Targeting PI3K in cancer: any good news? Front Oncol 3: 108, 2013.
14. Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8- phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248, 1994.
15. Tumaneng K, Russell RC and Guan KL: Organ size control by Hippo and TOR pathways. Curr Biol 22: R368-R379, 2012.
16. Steinhardt AA, Gayyed MF, Klein AP, et al: Expression of Yes-associated protein in common solid tumors. Hum Pathol 39: 1582-1589, 2008.
17. Konsavage WM Jr, Kyler SL, Rennoll SA, Jin G and Yochum GS: Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem 287: 11730-11739, 2012.
18. Avruch J, Zhou D and Bardeesy N: YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 11: 1090-1096, 2012.
19. Zhou D, Zhang Y, Wu H, et al: Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA 108: E1312-1320, 2011.
20. Yuen HF, McCrudden CM, Huang YH, et al: TAZ expression as a prognostic indicator in colorectal cancer. PloS One 8: e54211, 2013.
21. Kim SJ, Chung MJ, Kim JS, et al: Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol 39: 1587-1591, 2011.
22. Kim SJ, Lee JS and Kim SM: 3,3'-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep 27: 1669-1673, 2012.
23. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
24. Ahmad A, Ali S, Ahmed A, et al: 3, 3′-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neuexpressing breast cancer cells. PloS One 8: e54657, 2013.
25. Bhatnagar N, Li X, Chen Y, Zhou X, Garrett SH and Guo B: 3,3′-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res 2: 581-589, 2009.
26. Kim YH, Kwon HS, Kim DH, et al: 3,3′-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis 15: 1164-1173, 2009.
27. Pappa G, Strathmann J, Lowinger M, Bartsch H and Gerhauser C: Quantitative combination effects between sulforaphane and 3,3′- diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 28: 1471-1477, 2007.
28. Li Y, Li X and Guo B: Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 70: 646-654, 2010.
29. Choi HJ, Lim do Y and Park JH: Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3′-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol 9: 39, 2009.
30. Gao N, Cheng S, Budhraja A, et al: 3,3′-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process. PloS One 7: e31783, 2012.
31. Kim AH, Khursigara G, Sun X, Franke TF and Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cellular Biol 21: 893-901, 2001.
32. Alessi DR, Andjelkovic M, Caudwell B, et al: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996.
33. Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer 13: 246-257, 2013.
34. Halder G and Johnson RL: Hippo signaling: growth control and beyond. Development 138: 9-22, 2011.
35. Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 7: 182-191, 2007.
36. Lu L, Li Y, Kim SM, et al: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 107: 1437-1442, 2010.
37. Camargo FD, Gokhale S, Johnnidis JB, et al: YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17: 2054-2060, 2007.
38. Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A and Pan D: The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 24: 2383-2388, 2010.
39. Ye X, Deng Y and Lai ZC: Akt is negatively regulated by Hippo signaling for growth inhibition in Drosophila. Dev Biol 369: 115-123, 2012.
40. Cinar B, Fang PK, Lutchman M, et al: The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J 26: 4523-4534, 2007.